Abiopharma

🔍 STEINMAN LAWRENCE (Director)

Company: Pasithea Therapeutics Corp. (KTTA)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Acquired 152,783 shares of Stock Option (right to buy) at $0.841 per share (Derivative)
  Date: 2026-05-01 | Code: A | Expires: 2036-04-30 | equity_swap_involved: 0 | shares_owned_after: 152,783.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: The option (the "Option") award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan, as amended (the "Plan"). The shares of the Issuer's common stock, par value $0.0001 per share, underlying the Option will vest in full upon the one-year anniversary of the date of grant; provided, that the Reporting Person remains a director of the Issuer through such vesting date; provided further, that the shares underlying the Option will fully vest upon a Change in Control (as defined in the Plan).